HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Benny Weksler Michael E. Burt Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weksler, B. Articles by Burt, M. E. Search for Related Content PubMed PubMed Citation Articles by Weksler, B. Articles by Burt, M. E.

Ann Thorac Surg 1995;60:624-629
© 1995 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Isolated Single-Lung Perfusion: A Study of the Optimal Perfusate and Other Pharmacokinetic Factors

Thoracic Oncology Laboratory, Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

Accepted for publication April 6, 1995.

Background. Isolated single-lung perfusion with doxorubicin hydrochloride was shown to be effective in clearing experimental sarcoma lung metastases in the rat. The best perfusate to be used for isolated lung perfusion and factors affecting the final lung concentration of doxorubicin are the subject of the present study.

Methods. In experiment 1, 60 animals were randomized to undergo isolated left lung perfusion with doxorubicin with six different perfusates (n = 10 per group): saline, low-potassium–dextran, 5% albumin, 6% hetastarch, 5% buffered albumin, and 6% buffered hetastarch. Five animals served as negative controls. After perfusion, the lung wet to dry ratio and final lung doxorubicin concentration were determined. In experiment 2, 60 animals underwent isolated left lung perfusion with either 80 µg/mL or 320 µg/mL of doxorubicin. Animals were perfused at either 0.5 mL/min or 1 mL/min and for 2, 6, or 10 minutes. At the end of the perfusion period, the left lung doxorubicin concentration was measured. Statistical analysis included analysis of variance, the Duncan test for multiple comparisons, and multiple linear regression analysis. Significance was defined as a p value of less than 0.05.

Results. In experiment 1, perfusion with 6% buffered hetastarch resulted in the lowest lung wet to dry ratio, significantly different from all groups except the controls. Perfusion with low-potassium–dextran solution led to the highest final lung concentration of doxorubicin. In experiment 2, a model to predict final lung doxorubicin concentration was constructed: Log (final lung concentration) = 1.9 + 0.0071 • P + 0.186 • T, where P is the measured perfusate concentration of doxorubicin, and T is the time of perfusion in minutes. The R² was 0.91 and p, less than 0.001. The dose of doxorubicin per kilogram of animal body weight, the dose of doxorubicin per square meter of body surface area, the total amount of doxorubicin delivered, and the rate of perfusion did not meet the criteria to enter the equation.

Conclusions. Isolated lung perfusion experiments should use 6% buffered hetastarch as the perfusate. The perfusate doxorubicin concentration and the duration of perfusion are the only factors determining the final lung concentration of doxorubicin. In lung perfusion experiments, the dose of chemotherapy is not as important as the perfusate concentration and the duration of the perfusion. Animals should be perfused at a lower rate so the lungs are exposed to less doxorubicin without changing the final lung concentration.

This article has been cited by other articles:

				P. E. Van Schil, J. M. Hendriks, B. P. van Putte, B. A. Stockman, P. R. Lauwers, P. W. ten Broecke, M. J. Grootenboers, and F. M. Schramel Isolated lung perfusion and related techniques for the treatment of pulmonary metastases Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 487 - 496. [Abstract] [Full Text] [PDF]

				B. P. Van Putte, J. M.H. Hendriks, S. Romijn, G. Guetens, G. De Boeck, E. A. De Bruijn, and P. E.Y. Van Schil Single-pass isolated lung perfusion versus recirculating isolated lung perfusion with melphalan in a rat model Ann. Thorac. Surg., September 1, 2002; 74(3): 893 - 898. [Abstract] [Full Text] [PDF]

				P. Schneider, S. Kampfer, C. Loddenkemper, T. Foitzik, and H. J. Buhr Chemoembolization of the Lung Improves Tumor Control in a Rat Model Clin. Cancer Res., July 1, 2002; 8(7): 2463 - 2468. [Abstract] [Full Text] [PDF]

				T. Tanaka, Y. Kaneda, T.-S. Li, T. Matsuoka, N. Zempo, and K. Esato Digitonin enhances the antitumor effect of cisplatin during isolated lung perfusion Ann. Thorac. Surg., October 1, 2001; 72(4): 1173 - 1178. [Abstract] [Full Text] [PDF]

				J. M.H. Hendriks, P. E.Y. Van Schil, G. De Boeck, P. R.M. Lauwers, A. A.T. Van Oosterom, E. A.E. Van Marck, and E. J.M. Eyskens Isolated lung perfusion with melphalan and tumor necrosis factor for metastatic pulmonary adenocarcinoma Ann. Thorac. Surg., November 1, 1998; 66(5): 1719 - 1725. [Abstract] [Full Text] [PDF]

				M. Furrer, D. Lardinois, W. Thormann, H.-J. Altermatt, D. Betticher, J. Triller, D. Mettler, U. Althaus, M. E. Burt, and H.-B. Ris Cytostatic Lung Perfusion by Use of an Endovascular Blood Flow Occlusion Technique Ann. Thorac. Surg., June 1, 1998; 65(6): 1523 - 1528. [Abstract] [Full Text] [PDF]

				M. Furrer, D. Lardinois, W. Thormann, H. J. Altermatt, D. Betticher, T. Cerny, A. Fikrle, D. Mettler, U. Althaus, M. E. Burt, et al. Isolated Lung Perfusion: Single-Pass System Versus Recirculating Blood Perfusion in Pigs Ann. Thorac. Surg., May 1, 1998; 65(5): 1420 - 1425. [Abstract] [Full Text] [PDF]